MDxHealth stock faces reset as company suspends 2026 guidance

MDxHealth said on October 15 that preliminary third-quarter revenue from continuing operations was 22.7 million US dollars, matching the re-presented figure for the year-earlier quarter. In the same release, the company suspended its full-year 2026 revenue guidance of 110 million to 115 million US dollars.

The announcement puts execution and the upcoming full results at the center of the investment case. MDxHealth said third-quarter revenue fell short of its expectations after the discontinuation of Resolve mdx was followed by unexpected sales-force turnover. Management said it is working to strengthen affected territories and return to consistent execution.

Test volumes show a mixed picture

Tissue-based test volume, including Confirm mdx and GPS mdx, fell 11 percent year over year to 11,232 tests. Liquid-based test volume for Exo mdx rose to 11,792 tests from 4,600 in the comparable period, although the prior-year figure included Select mdx and Exo mdx after the September 2025 acquisition.

Cash and cash equivalents stood at 31.7 million US dollars on September 30. The figures are preliminary and unaudited, and the company cautioned that final results may differ after its quarter-end closing and review procedures.

November results set the next test

MDxHealth plans to report its complete third-quarter results and hold an earnings call on November 12. Investors will be watching for the scale of the sales-force disruption, the pace of territory recovery and any replacement for the suspended full-year outlook. The company said it still expects to return to growth in its end markets, but that statement remains forward-looking.

The announcement was made in a company press release.

Business remains focused on urology

MDxHealth provides precision diagnostics that use genomic, epigenomic, exosomal and other molecular technologies to support the diagnosis and prognosis of prostate cancer and other urologic diseases. Its commercial portfolio includes Confirm mdx, GPS mdx and Exo mdx, with operations centered on the United States and the company incorporated in Belgium.

MDxHealth occupies a specialized urology-focused position compared with broader diagnostics businesses such as Exact Sciences, LabCorp and Quest Diagnostics. Those peers have wider oncology or laboratory-service footprints, while MDxHealth concentrates its testing and clinical applications on urologic disease.

The broader US equity market remains an important backdrop for Nasdaq-listed healthcare companies; follow the S&P 500 for market context.

More news and analyses on MDxHealth stock.

MDxHealth at a glance

• Company: MDxHealth SA
• ISIN: BE0974461940
• Ticker: MDXH
• Primary listing: Nasdaq
• Business: Urology-focused precision diagnostics